ACE-031
Also known as: ActRIIB-Fc, Ramatercept
Soluble ActRIIB decoy receptor (Fc-fusion); traps myostatin and other TGF-β ligands to promote muscle growth and reduce fat.
- Typical dose
- 100 mcg – 500 mcg
- Frequency
- twice weekly
- Route
- Subcutaneous
- Half-life
- 10 days
- Routes
- Subcutaneous
- Status
- Development permanently discontinued (2013): vascular safety signals
Benefits
- Significant muscle mass increase
- Fat reduction
- Bone mineral density improvement
- Duchenne MD (investigational)
Dosing
A common research range for ACE-031 is 100 mcg to 500 mcg twice weekly. Development paused due to safety signals; experimental only. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Reconstitution
A typical reconstitution for ACE-031 is 1 mg of peptide in 1 mL of bacteriostatic water, giving roughly 1 mg per mL. Vial's built-in calculator works out the exact syringe draw for any vial size and dose.
Half-life
ACE-031 has an approximate half-life of 10 days. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.
Storage
2-8°C.
Reported side effects
- Nosebleeds
- Gum bleeding
- Dilated blood vessels
- Telangiectasia
Contraindications
- Bleeding disorders
- Vascular conditions
- Pregnancy
Track ACE-031 with Vial
Vial logs every ACE-031 dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. ACE-031 is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.